Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Common Equity (2017 - 2025)

Serina Therapeutics' Common Equity history spans 9 years, with the latest figure at $1.8 million for Q3 2025.

  • For Q3 2025, Common Equity rose 112.73% year-over-year to $1.8 million; the TTM value through Sep 2025 reached $1.8 million, up 112.73%, while the annual FY2024 figure was $641000.0, 101.98% up from the prior year.
  • Common Equity for Q3 2025 was $1.8 million at Serina Therapeutics, up from $1.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $1.8 million in Q3 2025 and bottomed at -$37.8 million in Q4 2022.
  • The 5-year median for Common Equity is -$13.3 million (2022), against an average of -$16.0 million.
  • The largest annual shift saw Common Equity plummeted 1527.47% in 2021 before it skyrocketed 112.73% in 2025.
  • A 5-year view of Common Equity shows it stood at -$11.9 million in 2021, then crashed by 218.13% to -$37.8 million in 2022, then rose by 14.52% to -$32.3 million in 2023, then soared by 101.98% to $641000.0 in 2024, then skyrocketed by 174.57% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Common Equity are $1.8 million (Q3 2025), $1.6 million (Q2 2025), and $1.6 million (Q1 2025).